🇺🇸 FDA
Patent

US 7538108

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

granted A61KA61K31/5383A61K31/675

Quick answer

US patent 7538108 (Prodrugs of 2,4-pyrimidinediamine compounds and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon May 21 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue May 26 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 21 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/5383, A61K31/675, A61P, A61P1/04